State Street Corp Has $8.33 Million Stake in Iradimed Corporation (NASDAQ:IRMD)

State Street Corp cut its holdings in Iradimed Corporation (NASDAQ:IRMD) by 2.0% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 165,533 shares of the medical equipment provider’s stock after selling 3,383 shares during the period. State Street Corp owned about 1.31% of Iradimed worth $8,325,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of the business. Isthmus Partners LLC raised its stake in shares of Iradimed by 1.1% in the second quarter. Isthmus Partners LLC now owns 72,664 shares of the medical equipment provider’s stock valued at $32,000 after buying an additional 759 shares during the period. Huntington National Bank increased its position in shares of Iradimed by 51.3% during the third quarter. Huntington National Bank now owns 1,487 shares of the medical equipment provider’s stock valued at $75,000 after buying an additional 504 shares during the period. Gladius Capital Management LP lifted its stake in Iradimed by 126.6% in the 3rd quarter. Gladius Capital Management LP now owns 1,727 shares of the medical equipment provider’s stock worth $87,000 after purchasing an additional 965 shares in the last quarter. Quantbot Technologies LP grew its position in Iradimed by 83.0% during the third quarter. Quantbot Technologies LP now owns 2,320 shares of the medical equipment provider’s stock worth $117,000 after buying an additional 1,052 shares in the last quarter. Finally, SG Americas Securities LLC bought a new position in Iradimed in the 3rd quarter worth about $147,000. Institutional investors own 92.34% of the company’s stock.

Insider Activity

In other news, CFO John Glenn sold 2,500 shares of the company’s stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $54.18, for a total value of $135,450.00. Following the completion of the sale, the chief financial officer now owns 4,383 shares of the company’s stock, valued at approximately $237,470.94. This represents a 36.32 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 37.10% of the company’s stock.

Iradimed Price Performance

Shares of Iradimed stock opened at $54.67 on Friday. Iradimed Corporation has a 1 year low of $40.18 and a 1 year high of $57.95. The firm has a market cap of $692.83 million, a PE ratio of 37.45 and a beta of 0.82. The company has a 50 day simple moving average of $53.24 and a two-hundred day simple moving average of $48.62.

Iradimed Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Monday, November 25th. Stockholders of record on Friday, November 15th were issued a $0.15 dividend. This represents a $0.60 dividend on an annualized basis and a dividend yield of 1.10%. The ex-dividend date of this dividend was Friday, November 15th. Iradimed’s payout ratio is currently 41.10%.

Iradimed Company Profile

IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices and related accessories, and disposables and services in the United States and internationally. It offers MRidium MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; MRI compatible patient vital signs monitoring system; and 3600 FMD1 with RALU ferromagnetic detection device.